In the studies by Papa et al. (2013) and Morisco et al. (2013), none of the IBD patients experienced HCV reactivation during anti-TNF-α therapy, confirming the long-term safety of this therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.